Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.32 |
| ▸ | CCR4 | P51679 | 3/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3378464 | 0.89 | GCK (0.41) | GCKTRPV1KITMEN1KMT2A | |
| SCHEMBL3379209 | 0.87 | GCK (0.39) | GCKGRM5MEN1KMT2AGAA | |
| SCHEMBL3380809 | 0.84 | SLC2A1 (0.34) | GCKLMNAKITGRM5MEN1 | |
| SCHEMBL3379021 | 0.80 | GAA (0.38) | GCKKITMEN1KMT2AGAA | |
| SCHEMBL3379194 | 0.80 | GAA (0.39) | GCKMEN1KMT2AGAAMAPT | |
| SCHEMBL3379007 | 0.78 | GRM5 (0.38) | GRM5 | |
| SCHEMBL3382496 | 0.77 | GCK (0.44) | GCKMEN1KMT2AGAAMAPT | |
| SCHEMBL3379603 | 0.76 | GCK (0.40) | GCKMEN1KMT2AGAAMAPT | |
| SCHEMBL3379571 | 0.76 | MEN1 (0.40) | GCKKITMEN1KMT2AGAA | |
| SCHEMBL3378923 | 0.76 | GCK (0.47) | GCKMEN1KMT2AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1934216-B1 | NAPHTHYRIDIN DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-11-24 | — | — | EP | claimed |
| US-7511055-B2 | Naphthyridin derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-31 | — | — | US | claimed |
| EP-1934216-A1 | NAPHTHYRIDIN DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | claimed |
| WO-2007039512-A1 | NAPHTHYRIDIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | claimed |
| US-20070078155-A1 | Naphthyridin derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-05 | — | — | US | claimed |
| EP-1934216-B1 | NAPHTHYRIDIN DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-11-24 | — | — | EP | disclosed |
| US-7511055-B2 | Naphthyridin derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511055-B2 | Naphthyridin derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511055-B2 | Naphthyridin derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1934216-A1 | NAPHTHYRIDIN DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039512-A1 | NAPHTHYRIDIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039512-A1 | NAPHTHYRIDIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078155-A1 | Naphthyridin derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20070078155-A1 | Naphthyridin derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20070078155-A1 | Naphthyridin derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078155-A1 | Naphthyridin derivatives | GRM5, GRM3, GRM1 | GCK 3178/4885LMNA 3861/4885TRPV1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.